Literature DB >> 1907614

ATP-dependent K+ channels modulate vasoconstrictor responses to severe hypoxia in isolated ferret lungs.

C M Wiener1, A Dunn, J T Sylvester.   

Abstract

In normo- and hypoglycemic ferret lungs, the pulmonary vascular response to severe hypoxia (PiO2 less than or equal to 10 mmHg) is characterized by an initial intense vasoconstriction followed by marked vasodilation, whereas in hyperglycemic lungs, vasodilation is minimal, causing vasoconstriction to be sustained. In contrast, the response to moderate hypoxia is characterized by a slowly developing sustained vasoconstriction which is unaffected by glucose concentration. To determine the role of ATP-dependent K+ (KATP) channels in these responses, we examined the effects of cromakalim, which opens KATP channels, and glibenclamide, which closes them. During steady-state vasoconstriction induced in isolated ferret lungs by moderate hypoxia, cromakalim caused dose-dependent vasodilation (EC50 = 7 x 10(-7) M) which was reversed by glibenclamide (IC50 = 8 x 10(-7) M), indicating that KATP channels were present and capable of modulating vascular tone. During severe hypoxia in hypoglycemic lungs [( glucose] less than 1 mM), glibenclamide markedly inhibited the secondary vasodilation. Raising perfusate glucose concentration to 14 +/- 0.4 mM had the same effect. As a result, initial vasoconstrictor responses were well sustained. However, neither glibenclamide nor hyperglycemia affected vasoconstrictor responses to moderate hypoxia or KCl, indicating that effects during severe hypoxia were not due to nonspecific potentiation of vasoconstriction. These findings suggest that in the ferret lung (a) severe hypoxia decreased ATP concentration and thereby opened KATP channels, resulting in increased K+ efflux, hyperpolarization, vasodilation, and reversal of the initial vasoconstrictor response; and (b) hyperglycemia prevented this sequence of events.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1907614      PMCID: PMC295371          DOI: 10.1172/JCI115331

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  24 in total

Review 1.  Endothelium-derived hyperpolarizing factor: a new endogenous inhibitor from the vascular endothelium.

Authors:  S G Taylor; A H Weston
Journal:  Trends Pharmacol Sci       Date:  1988-08       Impact factor: 14.819

Review 2.  Adenosine 5'-triphosphate-sensitive potassium channels.

Authors:  F M Ashcroft
Journal:  Annu Rev Neurosci       Date:  1988       Impact factor: 12.449

Review 3.  Ion channels and regulation of intracellular calcium in vascular endothelial cells.

Authors:  D J Adams; J Barakeh; R Laskey; C Van Breemen
Journal:  FASEB J       Date:  1989-10       Impact factor: 5.191

4.  Glyburide blocks the relaxation response to BRL 34915 (cromakalim), minoxidil sulfate and diazoxide in vascular smooth muscle.

Authors:  R J Winquist; L A Heaney; A A Wallace; E P Baskin; R B Stein; M L Garcia; G J Kaczorowski
Journal:  J Pharmacol Exp Ther       Date:  1989-01       Impact factor: 4.030

5.  Effects of glucose on hypoxic vasoconstriction in isolated ferret lungs.

Authors:  C M Wiener; J T Sylvester
Journal:  J Appl Physiol (1985)       Date:  1991-01

6.  In vitro and in vivo comparison of two K+ channel openers, diazoxide and cromakalim, and their inhibition by glibenclamide.

Authors:  U Quast; N S Cook
Journal:  J Pharmacol Exp Ther       Date:  1989-07       Impact factor: 4.030

7.  Hyperpolarizing vasodilators activate ATP-sensitive K+ channels in arterial smooth muscle.

Authors:  N B Standen; J M Quayle; N W Davies; J E Brayden; Y Huang; M T Nelson
Journal:  Science       Date:  1989-07-14       Impact factor: 47.728

8.  Effect of severe hypoxia on the pulmonary vascular response to vasoconstrictor agents.

Authors:  A L Harabin; M D Peake; J T Sylvester
Journal:  J Appl Physiol Respir Environ Exerc Physiol       Date:  1981-03

9.  Effects of cyclo- and lipoxygenase inhibitors on hypoxic vasoconstriction in isolated ferret lungs.

Authors:  J E Gottlieb; M McGeady; N F Adkinson; J T Sylvester
Journal:  J Appl Physiol (1985)       Date:  1988-03

10.  Glibenclamide is a competitive antagonist of cromakalim, pinacidil and RP 49356 in guinea-pig pulmonary artery.

Authors:  M Eltze
Journal:  Eur J Pharmacol       Date:  1989-06-20       Impact factor: 4.432

View more
  7 in total

Review 1.  Muscle KATP channels: recent insights to energy sensing and myoprotection.

Authors:  Thomas P Flagg; Decha Enkvetchakul; Joseph C Koster; Colin G Nichols
Journal:  Physiol Rev       Date:  2010-07       Impact factor: 37.312

2.  Role of KATP and L-type Ca2+ channel activities in regulation of ovine uterine vascular contractility: effect of pregnancy and chronic hypoxia.

Authors:  Daliao Xiao; Lawrence D Longo; Lubo Zhang
Journal:  Am J Obstet Gynecol       Date:  2010-12       Impact factor: 8.661

3.  Hypoxia modulates cyclic AMP activation of BkCa channels in rat pulmonary arterial smooth muscle.

Authors:  Scott A Barman; Shu Zhu; Richard E White
Journal:  Lung       Date:  2005 Sep-Oct       Impact factor: 2.584

4.  Acute hypoxia selectively inhibits KCNA5 channels in pulmonary artery smooth muscle cells.

Authors:  Oleksandr Platoshyn; Elena E Brevnova; Elyssa D Burg; Ying Yu; Carmelle V Remillard; Jason X-J Yuan
Journal:  Am J Physiol Cell Physiol       Date:  2005-10-19       Impact factor: 4.249

Review 5.  Potential adverse effects of bronchodilators in the treatment of airways obstruction in older people: recommendations for prescribing.

Authors:  Preeti Gupta; M Sinead O'Mahony
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

Review 6.  Potassium channels and uterine vascular adaptation to pregnancy and chronic hypoxia.

Authors:  Ronghui Zhu; DaLiao Xiao; Lubo Zhang
Journal:  Curr Vasc Pharmacol       Date:  2013-09       Impact factor: 2.719

Review 7.  Hypoxic pulmonary vasoconstriction.

Authors:  J T Sylvester; Larissa A Shimoda; Philip I Aaronson; Jeremy P T Ward
Journal:  Physiol Rev       Date:  2012-01       Impact factor: 46.500

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.